Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

Enhancing the efficacy of proteasome inhibitors (PI) is a central goal in myeloma therapy. We proposed that signaling-level responses after PI may reveal new mechanisms of action that can be therapeutically exploited. Unbiased phosphoproteomics after treatment with the PI carfilzomib surprisingly de...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hector H., Ferguson, Ian D., Thornton, Alexis M., Bastola, Prabhakar, Lam, Christine, Lin, Yu-Hsiu T., Choudhry, Priya, Mariano, Margarette C., Marcoulis, Makeba D., Teo, Chin Fen, Malato, Julia, Phojanakong, Paul J., Martin, Thomas G., Wolf, Jeffrey L., Wong, Sandy W., Shah, Nina, Hann, Byron, Brooks, Angela N., Wiita, Arun P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176739/
https://www.ncbi.nlm.nih.gov/pubmed/32321912
http://dx.doi.org/10.1038/s41467-020-15521-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176739/
https://www.ncbi.nlm.nih.gov/pubmed/32321912
http://dx.doi.org/10.1038/s41467-020-15521-4

Ejemplares similares